Julian Marshall - Volpara Health Chief Marketing Officer
| VPAHFDelisted Stock | USD 0.74 0.00 0.00% |
Executive
Mr. Julian Marshall is Chief Marketing Officer of the Company. He is a breast imaging expert of 30 years experience whose breadth of knowledge spans all major areas of the medical imaging industry. Initially a software developer and consultant for Sun Microsystems, Julian ran Alpine Image Systems for 8 years before joining companies like R2 Technology, acquired by Hologic in 2006. At R2 and Hologic he held leadership roles in software and hardware development, marketing and product management. In this last capacity he continued his work in product innovation for Hologic, where he served in several directorlevel positions. He led the team responsible for managing all of Hologics breast imaging products, including tomosynthesis, before moving to Hologics Global Strategic Innovation group. An engineer by training, Julian holds numerous patents in computeraided detection and breast imaging, including user interface design, and has worked in cardiac ultrasound, digital subtraction angiography, image processing and mammography. He is based in San Francisco, California.
| Phone | 64 4 499 6029 |
| Web | https://www.volparahealth.com |
Volpara Health Management Efficiency
The company has return on total asset (ROA) of (0.1099) % which means that it has lost $0.1099 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2198) %, meaning that it generated substantial loss on money invested by shareholders. Volpara Health's management efficiency ratios could be used to measure how well Volpara Health manages its routine affairs as well as how well it operates its assets and liabilities.Volpara Health Technologies has accumulated 2.77 M in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Volpara Health Techn has a current ratio of 1.43, which is within standard range for the sector. Debt can assist Volpara Health until it has trouble settling it off, either with new capital or with free cash flow. So, Volpara Health's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Volpara Health Techn sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Volpara to invest in growth at high rates of return. When we think about Volpara Health's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| James Hart | Progyny | N/A | |
| Jens Durruthy | 10X Genomics | N/A | |
| Maureen McKinney | Phreesia | N/A | |
| Arielle Bogorad | Progyny | N/A | |
| Stephany Verstraete | Teladoc | 55 | |
| Ashwin Uttamchandani | Phreesia | N/A | |
| Mennah Moustafa | 10X Genomics | N/A | |
| Kevin OHara | HealthStream | 54 | |
| Ram Sharma | Definitive Healthcare Corp | N/A | |
| Lewis Levy | Teladoc | 60 | |
| Scott Wagner | Goodrx Holdings | 53 | |
| Jack Callahan | Phreesia | N/A | |
| Jim Goodrich | 10X Genomics | N/A | |
| Alexander Wong | 10X Genomics | N/A | |
| Rona Anhalt | Certara | 59 | |
| Allison JD | Phreesia | 53 | |
| Justin Fengler | Goodrx Holdings | N/A | |
| Michael Waters | Teladoc | 51 | |
| Cassie Corneau | 10X Genomics | N/A | |
| Risa Fisher | Progyny | N/A | |
| Nikolaos Nanis | Teladoc | 49 | |
Management Performance
| Return On Equity | -0.22 | |||
| Return On Asset | -0.11 |
Volpara Health Techn Leadership Team
Elected by the shareholders, the Volpara Health's board of directors comprises two types of representatives: Volpara Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Volpara. The board's role is to monitor Volpara Health's management team and ensure that shareholders' interests are well served. Volpara Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Volpara Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tana Isaac, Ex Technology | ||
| Pr Karssemeijer, CoFounder Board | ||
| Jill Spear, Ex Marketing | ||
| JD BSc, Joint Counsel | ||
| Teri Thomas, MD CEO | ||
| Gareth Beaumont, Chief Officer | ||
| Julian Marshall, Chief Marketing Officer | ||
| Craig Hadfield, CFO, Joint Company Secretary | ||
| Kathryn Greene, Chief Officer |
Volpara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Volpara Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.43) % | |||
| Operating Margin | (0.50) % | |||
| Current Valuation | 95.01 M | |||
| Shares Outstanding | 252.16 M | |||
| Shares Owned By Insiders | 24.91 % | |||
| Shares Owned By Institutions | 18.89 % | |||
| Price To Book | 3.46 X | |||
| Price To Sales | 3.71 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Volpara Pink Sheet
If you are still planning to invest in Volpara Health Techn check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Volpara Health's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |